KR100270508B1 - Novel cephalosporin diacetylase gene and protein production method using the same - Google Patents
Novel cephalosporin diacetylase gene and protein production method using the same Download PDFInfo
- Publication number
- KR100270508B1 KR100270508B1 KR1019980014790A KR19980014790A KR100270508B1 KR 100270508 B1 KR100270508 B1 KR 100270508B1 KR 1019980014790 A KR1019980014790 A KR 1019980014790A KR 19980014790 A KR19980014790 A KR 19980014790A KR 100270508 B1 KR100270508 B1 KR 100270508B1
- Authority
- KR
- South Korea
- Prior art keywords
- cephalosporin
- enzyme
- kfcc11029
- coli
- seq
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 51
- 229930186147 Cephalosporin Natural products 0.000 title claims abstract description 22
- 229940124587 cephalosporin Drugs 0.000 title claims abstract description 22
- 150000001780 cephalosporins Chemical class 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 230000014616 translation Effects 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 claims abstract description 63
- 102000004190 Enzymes Human genes 0.000 claims abstract description 63
- 241000588724 Escherichia coli Species 0.000 claims abstract description 15
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 7
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000003381 deacetylation reaction Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 16
- 230000009257 reactivity Effects 0.000 abstract description 10
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Natural products S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 6
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 abstract description 5
- 239000000543 intermediate Substances 0.000 abstract description 5
- -1 diacetyl cephalosporin C Chemical compound 0.000 abstract description 4
- 108010013043 Acetylesterase Proteins 0.000 abstract description 3
- 230000006798 recombination Effects 0.000 abstract description 3
- 239000002689 soil Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 abstract 1
- 108010091086 Recombinases Proteins 0.000 abstract 1
- 102000018120 Recombinases Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 11
- 239000007983 Tris buffer Substances 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 4
- HOKIDJSKDBPKTQ-GLXFQSAKSA-M cephalosporin C(1-) Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H]([NH3+])C([O-])=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-M 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 3
- JKDBRTNMYXYLHO-JYJNAYRXSA-N Gln-Tyr-Leu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 JKDBRTNMYXYLHO-JYJNAYRXSA-N 0.000 description 3
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 3
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 3
- OMNVOTCFQQLEQU-CIUDSAMLSA-N His-Asn-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMNVOTCFQQLEQU-CIUDSAMLSA-N 0.000 description 3
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 3
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 3
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 3
- IRRZDAIFYHNIIN-JYJNAYRXSA-N Lys-Gln-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IRRZDAIFYHNIIN-JYJNAYRXSA-N 0.000 description 3
- LMKSBGIUPVRHEH-FXQIFTODSA-N Met-Ala-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(N)=O LMKSBGIUPVRHEH-FXQIFTODSA-N 0.000 description 3
- DZVXMMSUWWUIQE-ACRUOGEOSA-N Phe-His-Tyr Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N DZVXMMSUWWUIQE-ACRUOGEOSA-N 0.000 description 3
- MGLBSROLWAWCKN-FCLVOEFKSA-N Phe-Phe-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MGLBSROLWAWCKN-FCLVOEFKSA-N 0.000 description 3
- YUPRIZTWANWWHK-DZKIICNBSA-N Phe-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N YUPRIZTWANWWHK-DZKIICNBSA-N 0.000 description 3
- HBTCFCHYALPXME-HTFCKZLJSA-N Ser-Ile-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HBTCFCHYALPXME-HTFCKZLJSA-N 0.000 description 3
- LRZLZIUXQBIWTB-KATARQTJSA-N Ser-Lys-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRZLZIUXQBIWTB-KATARQTJSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DDRBQONWVBDQOY-GUBZILKMSA-N Val-Ala-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DDRBQONWVBDQOY-GUBZILKMSA-N 0.000 description 3
- NYTKXWLZSNRILS-IFFSRLJSSA-N Val-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N)O NYTKXWLZSNRILS-IFFSRLJSSA-N 0.000 description 3
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 3
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 108010017391 lysylvaline Proteins 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 description 2
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 2
- DVJSJDDYCYSMFR-ZKWXMUAHSA-N Ala-Ile-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O DVJSJDDYCYSMFR-ZKWXMUAHSA-N 0.000 description 2
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 2
- IZSMEUDYADKZTJ-KJEVXHAQSA-N Arg-Tyr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IZSMEUDYADKZTJ-KJEVXHAQSA-N 0.000 description 2
- LTDGPJKGJDIBQD-LAEOZQHASA-N Asn-Val-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LTDGPJKGJDIBQD-LAEOZQHASA-N 0.000 description 2
- KGAJCJXBEWLQDZ-UBHSHLNASA-N Asp-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N KGAJCJXBEWLQDZ-UBHSHLNASA-N 0.000 description 2
- PWAIZUBWHRHYKS-MELADBBJSA-N Asp-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)N)C(=O)O PWAIZUBWHRHYKS-MELADBBJSA-N 0.000 description 2
- UXIPUCUHQBIQOS-SRVKXCTJSA-N Asp-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UXIPUCUHQBIQOS-SRVKXCTJSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- BJPPYOMRAVLXBY-YUMQZZPRSA-N Gln-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N BJPPYOMRAVLXBY-YUMQZZPRSA-N 0.000 description 2
- YKLNMGJYMNPBCP-ACZMJKKPSA-N Glu-Asn-Asp Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YKLNMGJYMNPBCP-ACZMJKKPSA-N 0.000 description 2
- ZQYZDDXTNQXUJH-CIUDSAMLSA-N Glu-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)N ZQYZDDXTNQXUJH-CIUDSAMLSA-N 0.000 description 2
- ARIORLIIMJACKZ-KKUMJFAQSA-N Glu-Pro-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ARIORLIIMJACKZ-KKUMJFAQSA-N 0.000 description 2
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 2
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 2
- JUGQPPOVWXSPKJ-RYUDHWBXSA-N Gly-Gln-Phe Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JUGQPPOVWXSPKJ-RYUDHWBXSA-N 0.000 description 2
- UPADCCSMVOQAGF-LBPRGKRZSA-N Gly-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)CN)C(O)=O)=CNC2=C1 UPADCCSMVOQAGF-LBPRGKRZSA-N 0.000 description 2
- WJGSTIMGSIWHJX-HVTMNAMFSA-N His-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N WJGSTIMGSIWHJX-HVTMNAMFSA-N 0.000 description 2
- AQCUAZTZSPQJFF-ZKWXMUAHSA-N Ile-Ala-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AQCUAZTZSPQJFF-ZKWXMUAHSA-N 0.000 description 2
- WUEIUSDAECDLQO-NAKRPEOUSA-N Ile-Ala-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)O)N WUEIUSDAECDLQO-NAKRPEOUSA-N 0.000 description 2
- HZMLFETXHFHGBB-UGYAYLCHSA-N Ile-Asn-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZMLFETXHFHGBB-UGYAYLCHSA-N 0.000 description 2
- XLCZWMJPVGRWHJ-KQXIARHKSA-N Ile-Glu-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N XLCZWMJPVGRWHJ-KQXIARHKSA-N 0.000 description 2
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 2
- ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 2
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 2
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 2
- KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 2
- BJWKOATWNQJPSK-SRVKXCTJSA-N Leu-Met-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N BJWKOATWNQJPSK-SRVKXCTJSA-N 0.000 description 2
- FYPWFNKQVVEELI-ULQDDVLXSA-N Leu-Phe-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 FYPWFNKQVVEELI-ULQDDVLXSA-N 0.000 description 2
- VULJUQZPSOASBZ-SRVKXCTJSA-N Leu-Pro-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O VULJUQZPSOASBZ-SRVKXCTJSA-N 0.000 description 2
- HEWWNLVEWBJBKA-WDCWCFNPSA-N Lys-Gln-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN HEWWNLVEWBJBKA-WDCWCFNPSA-N 0.000 description 2
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 2
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 2
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 2
- 102100036617 Monoacylglycerol lipase ABHD2 Human genes 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- KBVJZCVLQWCJQN-KKUMJFAQSA-N Phe-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KBVJZCVLQWCJQN-KKUMJFAQSA-N 0.000 description 2
- PTDAGKJHZBGDKD-OEAJRASXSA-N Phe-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O PTDAGKJHZBGDKD-OEAJRASXSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 2
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 2
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- JHBHMCMKSPXRHV-NUMRIWBASA-N Thr-Asn-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O JHBHMCMKSPXRHV-NUMRIWBASA-N 0.000 description 2
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 2
- WPRVVBVWIUWLOH-UFYCRDLUSA-N Tyr-Phe-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N WPRVVBVWIUWLOH-UFYCRDLUSA-N 0.000 description 2
- VSYROIRKNBCULO-BWAGICSOSA-N Tyr-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O VSYROIRKNBCULO-BWAGICSOSA-N 0.000 description 2
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 108010080434 cephalosporin-C deacetylase Proteins 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010092114 histidylphenylalanine Proteins 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BQIMPGFMMOZASS-CLZZGJSISA-N (6r,7r)-7-amino-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(CO)=C(C(O)=O)N2C(=O)[C@@H](N)[C@H]21 BQIMPGFMMOZASS-CLZZGJSISA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LLARVKAOQLUCQI-UHFFFAOYSA-L 4-benzamido-2,5-dimethoxybenzenediazonium;tetrachlorozinc(2-) Chemical compound [Cl-].[Cl-].Cl[Zn]Cl.COC1=CC([N+]#N)=C(OC)C=C1NC(=O)C1=CC=CC=C1.COC1=CC([N+]#N)=C(OC)C=C1NC(=O)C1=CC=CC=C1 LLARVKAOQLUCQI-UHFFFAOYSA-L 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HUUOZYZWNCXTFK-INTQDDNPSA-N Ala-His-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N HUUOZYZWNCXTFK-INTQDDNPSA-N 0.000 description 1
- PMQXMXAASGFUDX-SRVKXCTJSA-N Ala-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CCCCN PMQXMXAASGFUDX-SRVKXCTJSA-N 0.000 description 1
- GKAZXNDATBWNBI-DCAQKATOSA-N Ala-Met-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N GKAZXNDATBWNBI-DCAQKATOSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- VDCIPFYVCICPEC-FXQIFTODSA-N Asn-Arg-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O VDCIPFYVCICPEC-FXQIFTODSA-N 0.000 description 1
- PAXHINASXXXILC-SRVKXCTJSA-N Asn-Asp-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N)O PAXHINASXXXILC-SRVKXCTJSA-N 0.000 description 1
- VJTWLBMESLDOMK-WDSKDSINSA-N Asn-Gln-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O VJTWLBMESLDOMK-WDSKDSINSA-N 0.000 description 1
- ASCGFDYEKSRNPL-CIUDSAMLSA-N Asn-Glu-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O ASCGFDYEKSRNPL-CIUDSAMLSA-N 0.000 description 1
- GIQCDTKOIPUDSG-GARJFASQSA-N Asn-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N)C(=O)O GIQCDTKOIPUDSG-GARJFASQSA-N 0.000 description 1
- KFAFUJMGHVVYRC-DCAQKATOSA-N Asp-Leu-Met Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O KFAFUJMGHVVYRC-DCAQKATOSA-N 0.000 description 1
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 1
- UXRVDHVARNBOIO-QSFUFRPTSA-N Asp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)N UXRVDHVARNBOIO-QSFUFRPTSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- PSERKXGRRADTKA-MNXVOIDGSA-N Gln-Leu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PSERKXGRRADTKA-MNXVOIDGSA-N 0.000 description 1
- XZUUUKNKNWVPHQ-JYJNAYRXSA-N Gln-Phe-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O XZUUUKNKNWVPHQ-JYJNAYRXSA-N 0.000 description 1
- PAOHIZNRJNIXQY-XQXXSGGOSA-N Gln-Thr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PAOHIZNRJNIXQY-XQXXSGGOSA-N 0.000 description 1
- SDSMVVSHLAAOJL-UKJIMTQDSA-N Gln-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N SDSMVVSHLAAOJL-UKJIMTQDSA-N 0.000 description 1
- GCYFUZJHAXJKKE-KKUMJFAQSA-N Glu-Arg-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GCYFUZJHAXJKKE-KKUMJFAQSA-N 0.000 description 1
- CKRUHITYRFNUKW-WDSKDSINSA-N Glu-Asn-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CKRUHITYRFNUKW-WDSKDSINSA-N 0.000 description 1
- PCBBLFVHTYNQGG-LAEOZQHASA-N Glu-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N PCBBLFVHTYNQGG-LAEOZQHASA-N 0.000 description 1
- CUXJIASLBRJOFV-LAEOZQHASA-N Glu-Gly-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CUXJIASLBRJOFV-LAEOZQHASA-N 0.000 description 1
- NJPQBTJSYCKCNS-HVTMNAMFSA-N Glu-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N NJPQBTJSYCKCNS-HVTMNAMFSA-N 0.000 description 1
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 description 1
- UDEPRBFQTWGLCW-CIUDSAMLSA-N Glu-Pro-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O UDEPRBFQTWGLCW-CIUDSAMLSA-N 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 1
- MKIAPEZXQDILRR-YUMQZZPRSA-N Gly-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN MKIAPEZXQDILRR-YUMQZZPRSA-N 0.000 description 1
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 1
- WTJBVCUCLWFGAH-JUKXBJQTSA-N His-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N WTJBVCUCLWFGAH-JUKXBJQTSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- LIINDKYIGYTDLG-PPCPHDFISA-N Leu-Ile-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LIINDKYIGYTDLG-PPCPHDFISA-N 0.000 description 1
- DRCILAJNUJKAHC-SRVKXCTJSA-N Lys-Glu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DRCILAJNUJKAHC-SRVKXCTJSA-N 0.000 description 1
- GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- OIFHHODAXVWKJN-ULQDDVLXSA-N Met-Phe-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 OIFHHODAXVWKJN-ULQDDVLXSA-N 0.000 description 1
- LBSWWNKMVPAXOI-GUBZILKMSA-N Met-Val-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O LBSWWNKMVPAXOI-GUBZILKMSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- AAERWTUHZKLDLC-IHRRRGAJSA-N Phe-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O AAERWTUHZKLDLC-IHRRRGAJSA-N 0.000 description 1
- KUSYCSMTTHSZOA-DZKIICNBSA-N Phe-Val-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N KUSYCSMTTHSZOA-DZKIICNBSA-N 0.000 description 1
- QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UDNVOQMPQBEITB-MEYUZBJRSA-N Thr-His-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UDNVOQMPQBEITB-MEYUZBJRSA-N 0.000 description 1
- CJEHCEOXPLASCK-MEYUZBJRSA-N Thr-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=C(O)C=C1 CJEHCEOXPLASCK-MEYUZBJRSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- WEFIPBYPXZYPHD-HJPIBITLSA-N Tyr-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=C(C=C1)O)N WEFIPBYPXZYPHD-HJPIBITLSA-N 0.000 description 1
- AKLNEFNQWLHIGY-QWRGUYRKSA-N Tyr-Gly-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N)O AKLNEFNQWLHIGY-QWRGUYRKSA-N 0.000 description 1
- RUCNAYOMFXRIKJ-DCAQKATOSA-N Val-Ala-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RUCNAYOMFXRIKJ-DCAQKATOSA-N 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000007444 cell Immobilization Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- YGBFLZPYDUKSPT-MRVPVSSYSA-N cephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C[C@H]21 YGBFLZPYDUKSPT-MRVPVSSYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
토양에서 신규 세팔로스포린 디아세틸레이즈를 분비하는 신균주를 순수 분리 하여, 그 신균주를 동정한 결과 바실루스 종(Bacillus sp.)으로 확인하고 이 균주를 바실루스 DS1152로 명명하였다.New strains that secrete new cephalosporin diacetylase from the soil were purely isolated and identified as Bacillus sp. As a result of identifying the new strain, the strain was named Bacillus DS1152.
신균주 바실루스 DS1152(KFCC11026)로 부터 디아세틸 세팔로스포린 C, 디아세틸 7-ACA 및 디아세틸 2-메톡시미노-2-푸릴-아세틱 세팔로스포린산 생산에 관여하는, 신규 세팔로스포린 디아세틸레이즈 유전자를 분리하여, 유전자 서열 및 아미노산 배열을 분석하여 신규 효소임을 밝혔다.New cephalosporin di, involved in the production of diacetyl cephalosporin C, diacetyl 7-ACA and diacetyl 2-methoxymino-2-furyl-acetic cephalosporinic acid from the new strain Bacillus DS1152 (KFCC11026) Acetylase genes were isolated and analyzed for gene sequence and amino acid sequence to reveal new enzymes.
이 신규 유전자에 의해 코딩된 신규효소를 분리, 정제하여 생화학적 성질을 조사하였고 분리된 신규 효소의 유전자를 유전자 재조합 기술로 조작하여, 대장균(KFCC11029)에서 대량으로 증폭, 발현을 하였다. 이 때 발현된 효소는 분자량이 24KD이였으며, 구조 형태는 이중체로 구성되어 있으며 분자량 48KD이였다.The new enzymes encoded by this novel gene were isolated and purified to examine their biochemical properties, and the genes of the isolated novel enzymes were manipulated by genetic recombination technology to be amplified and expressed in large quantities in E. coli (KFCC11029). At this time, the expressed enzyme had a molecular weight of 24KD, and the structural form was composed of duplexes and had a molecular weight of 48KD.
이 신규 재조합효소는 다양한 세파로스포린계 중간체에 우수한 기질 반응성을 보유하고 있음을 균체 및 효소를 고정화하여 확인하였다. 이러한 신규 기술을 이용하여 세파로스포린계 반합성 중간체 제조에 응용함으로써, 기존의 합성법 보다 산업적으로 매우 유리한 신규 기술을 확립하였다.This novel recombinase was confirmed by immobilization of cells and enzymes having excellent substrate reactivity to various cephalosporin intermediates. By applying this novel technology to the preparation of the cephalosporin-based semisynthetic intermediate, a new technology which is very industrially advantageous over the existing synthetic method has been established.
Description
본 발명은 세팔로스포린계 항생제 제조에 필수적 전구체인, 세팔로스포린C 와 7-ACA(7-aminocephalosporanic acid)의 탈아세틸화 반응을 촉진하는 효소와 이의 유전자에 관한 것이다.The present invention relates to enzymes and genes for promoting deacetylation of cephalosporin C and 7-ACA (7-aminocephalosporanic acid), which are essential precursors for the preparation of cephalosporin-based antibiotics.
세팔로스포린C 와 7-ACA 같은 세파로스포린계 화합물은 3위치에 결합된 아세틸기가 제거됨으로서, 고부가가치 세파로스포린계 항생제 제조에 반합성 중간체로 이용된다. 세팔로스포린의 탈아세틸화 반응을 위한 방법으로는 화학적 방법과 효소적 방법이 있다. 이중 효소적 방법은 반응pH, 반응온도, 반응부산물 등에 의한 수율향상의 잇점들이 보고되고 있다.(USP3,304,236)Sephalosporin-based compounds such as cephalosporin C and 7-ACA are used as semisynthetic intermediates for the preparation of high value-added cephalosporin antibiotics by eliminating the acetyl group bound to the 3-position. Methods for deacetylation of cephalosporins include chemical and enzymatic methods. Dual enzymatic methods have been reported to improve yields by reaction pH, reaction temperature, reaction byproducts, etc. (USP3,304,236).
이러한 효소(Cephalosporin C Deacetylase)는 바실루스 서브틸리스(Bacillus subtilis; 고초균) 기원의 미생물에서 일본 시오노기(Shionogi)사에 의해 생화학적 특성이 구분되는 2종의 효소가 보고되었으며, 그 중 한 종의 효소는 대장균에 유전자를 도입하여 대량생산하는 방법으로 최근에 보고되었다.(EP0454478A1, Applied and Environmental Microbiology.1995.p2224)This enzyme (Cephalosporin C Deacetylase) has been reported two kinds of enzymes whose biochemical properties are distinguished by the Japanese Shionogi company from microorganisms of Bacillus subtilis origin. Enzymes have recently been reported as mass production by introducing genes into E. coli (EP0454478A1, Applied and Environmental Microbiology.1995.p2224).
본 발명자들은 대한민국 경기도 이천 근교의 토양에서 강력한 세팔로스포린C 디아세틸레이즈 활성을 가지는 바실루스 종(Bacillus sp. DS1152)을 분리하였으며, 이 균주로부터 활성효소를 코딩하는 신규유전자를 분리하였다. 분리된 유전자를 유전자 재조합법에 의해 대장균하에서 여러가지 벡터시스템으로 대량증폭 하였다. 그 증폭된 효소단백질의 생화학적 특성을 분석한 결과는 다음의 표 1과 같다. 이 결과에 의하면 기보고된(Shionogi사) 것과 효소의 생화학적 특성이 상이하게 구분되며, 특히 세파로스포린 씨에 대한 기질친화력과 반응성이 우수하였다.The present inventors isolated Bacillus sp. DS1152 having strong cephalosporin C deacetylase activity in soil near Icheon, Gyeonggi-do, Korea, and isolated a novel gene encoding an activating enzyme from this strain. The isolated gene was amplified in a large number of vector systems under E. coli by gene recombination. The results of analyzing the biochemical properties of the amplified enzyme protein are shown in Table 1 below. According to these results, the biochemical properties of the enzyme (Shionogi Co., Ltd.) and enzymes are different from each other, and the substrate affinity and reactivity of cephalosporin seeds are excellent.
표1. 효소단백질의 생화학적 특성Table 1. Biochemical Properties of Enzyme Proteins
본 발명에서 생산된 효소를 세팔로스포린계 항생제 제조 공정에 이용함으로써, 기존의 화학합성공정의 다단계 반응공정을 축소할 수 있고, 효소반응에 의하여 세팔로스포린계 항생제의 생산성을 향상시키는 새로운 방법을 제공하는데 그 목적이 있다.By using the enzyme produced in the present invention in the process for producing cephalosporin antibiotics, it is possible to reduce the multi-step reaction process of the existing chemical synthesis process, and to improve the productivity of the cephalosporin antibiotics by enzyme reaction. The purpose is to provide.
도 1 은 본 발명에 사용된 발현벡타에 유전자를 도입하는 플라스미드 재구성 과정이다.1 is a plasmid reconstitution process for introducing a gene into an expression vector used in the present invention.
본 연구의 바실루스 (Bacillus sp. DS1152(KFCC11026))는 토양으로부터 순수분리된 종균으로서 LB(Luria-Bertani) 평판배지에서 30℃에서 24시간 배양으로 균의 성장을 확인 할수 있으며 배양균의 특성은 다음과 같다.Bacillus sp. DS1152 (KFCC11026) of the present study is a seed isolated from soil and can be grown in LB (Luria-Bertani) plate medium for 24 hours at 30 ° C. Same as
표 2. 바실루스(Bacillus sp. DS1152(KFCC11026)) 균주특성Table 2. Bacillus sp. DS1152 (KFCC11026) strain characteristics
실시예 1 : 효소의 특성 분석Example 1 Characterization of Enzymes
(1) 효소의 분리 정제(1) Separation and Purification of Enzymes
LB 배양액을 첨가한 500ml 삼각 플라스크를 121℃에서 20분간 살균한 다음 바실루스 DS1152를 접종하여 30℃에서 9시간 전배양을 실시하여 이를 생산배지의 종균으로 사용하였다. 본 배양은 4.5L의 LB 배지가 첨가된 7.0L발효조를 121℃에서 20분간 살균한 다음 위의 배양된 전 배양액을 1%되게 첨가하여 30℃에서 48시간 배양한 후 이의 배양액으로부터 디아세틸레이즈를 아래와 같은 방법을 통하여 정제하였다. 위의 배양액으로 부터 원심분리(5000 rpm x 30분)하여 균체를 회수하였다. 50mM Tris/HCl(pH8.0)의 pH완충 용액을 이용하여 회수된 균체를 현탁시킨 다음, 초음파 균체 파쇄기를 이용하여 균체를 파쇄하였다. 이렇게 파쇄된 균체는 원심분리(12,000 rpm x 30분)를 통하여 물에 녹지않는 부분을 다시 제거하였으며, 원심분리 후 위의 상등액은 40 - 80% (NH4)2SO4포화용액을 이용한 단백질 분별 침전법을 이용하여 1차로 정제되었다. 이때 용액 중에는 많은 양의 염이 존재하므로 이를 제거하고 또한 단백질을 농축하기 위해서 한외여과를 실시하였으며 투과성막의 기공크기는 30KDa 이었다. 이렇게 농축된 단백질 용액은 50mM Tris/HCl(pH8.0)에서 안정화된 DEAE-세파로즈(pharmacia 제품)에 유속 2.0ml/min의 속도로 첨가되었으며 첨가량은 겔의 ml당 40mg의 단백질을 첨가하였다. 완전히 첨가된 후에 안정화에 이용되었던 완충용액으로 다시 칼럼을 씻어주고 단백질의 용리는 0 - 300 mM NaCl을 연속 농도구배 방법으로 흘려서 용리하였다. 이때 디아세틸레이즈의 대부분이 150 - 200mM의 NaCl농도 구간에서 용리되었으며 이들은 한 곳으로 모아져 다시 기공의 크기가 30KDa인 투과성 막을 이용한 한외여과 방법에 의해 농축되어 세파크릴-S300(Sephacryl-S300; pharmacia 제품)을 이용한 겔 크로마토그래피에 적용되어 최종적으로 분리 정제되었다. 이때 기질을 7-ACA로 하여 비활성도를 측정한 결과 단백질 mg당 31unit이었다.The 500 ml Erlenmeyer flask to which LB culture was added was sterilized at 121 ° C. for 20 minutes, and then inoculated with Bacillus DS1152 and pre-cultured at 30 ° C. for 9 hours, and used as a seed of the production medium. The culture was performed by sterilizing a 7.0 L fermentation tank containing 4.5 L of LB medium for 20 minutes at 121 ° C., then incubating for 48 hours at 30 ° C. by adding 1% of the above cultured whole culture solution to deacetylase from the culture medium. Purification was carried out as follows. Cells were recovered by centrifugation (5000 rpm x 30 minutes) from the above culture. The recovered cells were suspended using a pH buffer solution of 50 mM Tris / HCl (pH 8.0), and then the cells were crushed using an ultrasonic cell crusher. The pulverized cells were removed again in the insoluble part by centrifugation (12,000 rpm x 30 minutes). After centrifugation, the supernatant was fractionated by using 40-80% (NH 4 ) 2 SO 4 saturated solution. Purification was carried out primarily by precipitation. At this time, since a large amount of salt was present in the solution, the ultrafiltration was performed to remove it and to concentrate the protein. The pore size of the permeable membrane was 30 KDa. This concentrated protein solution was added to DEAE-Sepharose (pharmacia) stabilized in 50 mM Tris / HCl (pH 8.0) at a flow rate of 2.0 ml / min and the amount of 40 mg of protein per ml of gel was added. After complete addition, the column was washed again with the buffer used for stabilization, and the elution of the protein was eluted by flowing 0-300 mM NaCl in a continuous concentration gradient method. At this time, most of the deacetylase was eluted in the NaCl concentration range of 150-200mM, and they were collected in one place and concentrated again by ultrafiltration using a permeable membrane having a pore size of 30KDa. Sephacryl-S300 It was applied to gel chromatography using) and finally separated and purified. In this case, the activity was measured using the substrate as 7-ACA, and 31 units per mg of protein.
(2) 효소의 분자량 측정(2) determination of molecular weight of enzyme
효소의 전체적인 분자량 측정은 1.6 x 100cm(겔 부피:300ml)의 칼럼에 세파크릴-S300이 충진된 겔 크로마토그래피를 이용였다. 컬럼은 2.5ml/min의 유속하에 완충용액으로 200, 150, 66, 29, 19.3KDa (sigma 제품)의 표준단백질을 용리하였다. 동일한 방법으로 측정효소의 시료가 용리되는 완충용액의 부피를 표준시료와 비교하며 표준곡선 하에서 분자량을 계산하였다. 이때 계산된 효소의 분자량은 48KDa이었으며, 결과는 도 4와 같다. 또한 보조적으로 12%의 폴리 아크릴과 라밀리스(Lammilis)방법을 이용한 SDS-PAGE를 이용하여 단량체(monomer)의 분자량을 결정하였으며, 측정된 단량체(monomer)의 분자량은 24KDa에었다. 이로부터 활성효소는 분자량 24KDa의 단량체(monomer)가 이중체(dimer)로 구성된 효소임을 확인하였다.The overall molecular weight of the enzyme was determined by gel chromatography packed with Sephacryl-S300 in a column of 1.6 × 100 cm (gel volume: 300 ml). The column eluted standard protein of 200, 150, 66, 29, 19.3KDa (Sigma) in buffer at a flow rate of 2.5 ml / min. In the same way, the volume of the buffer solution in which the sample of the enzyme was eluted was compared with the standard sample and the molecular weight was calculated under the standard curve. At this time, the calculated molecular weight of the enzyme was 48KDa, the result is as shown in FIG. In addition, the molecular weight of the monomer was determined by using SDS-PAGE using 12% polyacrylamide and the Rammilis method, and the measured molecular weight of the monomer was 24KDa. From this, it was confirmed that the activating enzyme is an enzyme composed of a monomer having a molecular weight of 24 KDa.
(3) 효소의 아미노 말단부위의 아미노산서열 분석(3) Analysis of amino acid sequence of amino terminal region of enzyme
부분정제된 효소는(정제도:95%)는 증류수로 한외여과하여 염을 제거한 후 동결 건조하였으며, 이 시료를 단백질 염기서열 분석시스템(Precise Protein sequencing system: Applied Biosystems 제품)하에서 제시된 표준분석 메뉴얼에 따라 아미노 말단의 10base 아미노산 배열을 결정 하였다. 결정된 세팔로스포린 디아세틸레이즈 아미노 말단의 염기서열은 메치오닌이 아닌 Ala-Asn-His-Ile- Tyr-Leu-Ala-Gly-Asp-Ser의 순서임을 확인 하였다.The partially purified enzyme (purified: 95%) was ultrafiltered with distilled water to remove salts and freeze-dried, and the sample was subjected to the standard analysis manual presented under the Precise Protein sequencing system (Applied Biosystems). The amino acid sequence of the amino terminus 10base was determined accordingly. The determined base sequence of the cephalosporin diacetylase amino terminal was confirmed that the sequence of Ala-Asn-His-Ile-Tyr-Leu-Ala-Gly-Asp-Ser rather than methionine.
(4) 효소의 활성 측정(4) Determination of enzyme activity
시오노기등에 의해 실시된 예와 같이 0.1M 나트륨 인산 완충용액(pH7.0)을 사용하였으며, 효소의 활성도는 37℃에서 분당 1M의 7-ACA를 탈아세틸화시키는 양을 1unit로 정의 하였다. 실험에 사용된 효소는 앞서 실시된 정제 방법에 의해 준비된 효소를 진공건조 한 후 필요시 완충용액에 일정양을 녹여 사용하였다. 또한 7-ACA의 탈아세틸화 반응 산물인 디아세틸-7-아미노세팔로스포린산(deacetyl-7-aminocephalosporanic acid; 이하 DACA)의 정량 분석은 HPLC에 의해 해석되었으며 이용된 HPLC조건은 아래와 같다.0.1 M sodium phosphate buffer (pH 7.0) was used as in the example carried out by the Shiono group, and the enzyme activity was defined as 1 unit of deacetylating 1 M of 7-ACA per minute at 37 ° C. The enzyme used in the experiment was vacuum-dried the enzyme prepared by the purification method carried out before, and then dissolved in a certain amount in a buffer solution if necessary. In addition, the quantitative analysis of deacetyl-7-aminocephalosporanic acid (hereinafter referred to as DACA), which is a deacetylation reaction product of 7-ACA, was analyzed by HPLC and the HPLC conditions used were as follows.
표 3. HPLC 분석 조건Table 3. HPLC Analysis Conditions
(5) 효소의 최적 반응 pH 측정(5) Determination of optimum pH of enzyme
효소의 최적 pH를 측정하기 위해 pH3.0 - 11.0사이의 구간이 조사 되었으며 pH3.0 - 5.0의 산성 구간에서는 0.1M의 구연산 완충용액을 사용하였으며 pH6.0 - 11.0사의 구간에서는 0.05M의 나트륨 인산과 0.05M의 구연산을 첨가한 뒤 NaOH로 pH를 조정한 광범위 완충용액을 사용하였다. 또한 기질은 7-ACA를 사용하였으며 생성된 DACA와 소비된 기질은 앞서 제시된 HPLC조건을 통하여 분석되었다. 효소의 pH에 따른 반응성은 8.0 - 9.0에서 가장 높은 활성도를 보였다.In order to measure the optimum pH of the enzyme, the interval between pH3.0 and 11.0 was investigated, 0.1M citric acid buffer solution was used in the acidic range of pH3.0-5.0 and 0.05M sodium phosphate in the pH6.0-11.0 range. And 0.05M citric acid were added, and then a wide range of buffer solution was adjusted to pH with NaOH. In addition, 7-ACA was used as a substrate, and the produced DACA and the consumed substrate were analyzed by the HPLC conditions presented above. The pH-dependent reactivity of the enzyme showed the highest activity at 8.0-9.0.
(6) 효소의 최적 반응 온도 측정(6) determination of optimum reaction temperature of enzyme
효소의 최적 온도 분석을 위해 0.1M의 나트륨 인산 완충용액(pH7.0)이 사용되었으며 시험에 이용되는 온도 범위는 20 - 45℃의 구간에서 5℃의 간격으로 실시되었다. 또한 실험에 이용된 기질은 앞서 실시된 방법에 의해 기질은 7-ACA를 사용하였으며 분석은 앞서 제시된 HPLC조건을 통해 실시되었다. 효소 활성은 30℃에서부터 반응성이 증가되었으며, 40℃에서 가장 높은 활성도를 보였다.0.1 M sodium phosphate buffer (pH 7.0) was used for the optimal temperature analysis of the enzyme, and the temperature range used for the test was performed at intervals of 5 ° C. in the range of 20-45 ° C. In addition, the substrate used in the experiment was carried out by the method described above using the substrate 7-ACA and the analysis was carried out through the HPLC conditions presented above. Enzyme activity was increased from 30 ℃, the highest activity at 40 ℃.
(7) 효소의 등전점 측정(7) Determination of isoelectric point of enzyme
효소의 등전점에 관한 분석은 농도구배등전점 측정법 (iso-electrofocusing)을 통하여 실시되었으며 pH의 구간은 pH3.0 - 9.0의 구간이었다. 이때 표준 물질로서는 등전점이 pH4.7 - 4.9인 bovine serum albumin이 사용되었으며 실제 pH는 효소가 걸려있는 겔상의 위치를 잘라내어 겔속에 녹아있는 전해물질을 증류수에 녹여내어 pH를 측정하였다. 이때 측정된 효소의 pI값은 4.3을 보였다.The isoelectric point of the enzyme was analyzed by iso-electrofocusing, and the pH range was pH 3.0-9.0. At this time, bovine serum albumin with isoelectric point pH4.7-4.9 was used as the standard material, and the pH was measured by dissolving the electrolytic material dissolved in the gel in distilled water by cutting off the gel on the enzyme. At this time, the enzyme showed a pI value of 4.3.
(8) 효소의 기질 반응성(8) substrate reactivity of the enzyme
효소의 기질반응성은 미카엘리스(Michaelis) 상수로서 효소의 반응속도를 정의하였다. 효소의 반응을 위한 조건은 0.1M의 나트륨인산완충용액(pH7.0)에, 7-ACA, 세팔로스포린 C (이하 CPC), 2-메톡시미노-2-푸릴아세틱세팔로스포린산; 2-Methoxyimino-2-furylacetic cephalosporanic acid; 이하 MIFACA)의 기질을 농도를 달리하여 첨가한 후 37℃에서 10분간 반응시켜 HPLC로 분석하였다. 분석된 효소의 기질반응성은 Lineweaver-Burke식에 의해 계산하였다. 계산된 기질에 대한 반응성은 다음의 표와 같으며, 특히 세파로스포린계 중간체에 고른 반응성을 보였다.The substrate reactivity of the enzyme defined the reaction rate of the enzyme as the Michaelis constant. Conditions for the reaction of the enzyme were 0.1M sodium phosphate buffer solution (pH 7.0), 7-ACA, cephalosporin C (hereinafter CPC), 2-methoxymino-2-furylacephacelosporinic acid; 2-Methoxyimino-2-furylacetic cephalosporanic acid; Subsequently, the substrate of MIFACA) was added at different concentrations, followed by reaction at 37 ° C. for 10 minutes, and analyzed by HPLC. Substrate reactivity of the analyzed enzyme was calculated by Lineweaver-Burke equation. The calculated reactivity to the substrate is shown in the following table, and showed particularly even reactivity to the Sepharoserin-based intermediate.
표 4. 효소의 기질반응성Table 4. Substrate Reactivity of Enzymes
실시예 2 : 유전자 분리 및 염기서열분석Example 2 Gene Isolation and Sequence Analysis
(1) DNA 단리 및 유전자 라이브러리 제조(1) DNA isolation and gene library preparation
바실루스 DS1152를 LB 배양액, 30℃에서 24시간 배양후, 5000rpm x 10min 원심분리한후 4g의 균체를 회수하였으며, 이를 20mM 트리스 완충액(pH8.0) 20mL하에서 현탁하였다.Bacillus DS1152 was incubated for 24 hours at 30 ° C. in LB culture medium, and then 4 g of cells were recovered after centrifugation at 5000 rpm x 10 min, which was suspended in 20 mL of 20 mM Tris buffer (pH 8.0).
이를 20% PEG #8000 용액 10ml, 리소짐용액 1mL(100mg/ml)처리한후 37℃에서 4시간 반응하였다. 이것을 3500rpm x 20min 원심분리하여 상층액을 제거한후 100mM 트리스완충용액, 10mM EDTA 용액(pH8.0) 20mL하에서 혼합한후 25% SDS 1ml를 넣고 37℃에서 1시간 섞어 혼탁한후 프로테네이즈 K 용액(20mg/ml) 200μL를 첨가하여 4시간 반응하였다This was treated with 10 ml of 20% PEG # 8000 solution and 1 mL of lysozyme solution (100 mg / ml) and reacted at 37 ° C. for 4 hours. The supernatant was removed by centrifugation at 3500 rpm x 20 min, and then mixed under 20 mL of 100 mM Tris buffer solution and 10 mM EDTA solution (pH8.0). Then, 1 ml of 25% SDS was added and mixed for 1 hour at 37 ° C, followed by protease K solution. 200 μL (20 mg / ml) was added and reacted for 4 hours.
위의 반응액을 15ml 페놀/클로로포름/이소아밀알코올(25:24:1)하에서 12시간 교반한 후 12000rpm x 30min 원심분리하여 상층액을 취하였다. 취한 용액은 1.5ml 아세트산 완충용액(pH5.2), 냉각 에탄올 35ml을 처리하여 -70℃에서 15분간 정치 시켰다. 이를12000rpm x 10min 원심분리하여 상층액을 제거한후, 진공건조하여 10mM 트리스 완충용액, 1mM EDTA 용액(pH8.0) 500μL하에서 녹였다.The reaction solution was stirred for 12 hours under 15 ml phenol / chloroform / isoamyl alcohol (25: 24: 1), followed by centrifugation at 12000 rpm × 30 min to obtain a supernatant. The solution was treated with 1.5 ml of acetic acid buffer (pH5.2) and 35 ml of cold ethanol, and left to stand at -70 ° C for 15 minutes. The supernatant was removed by centrifugation at 12000 rpm x 10 min, followed by vacuum drying to dissolve in 500 μL of 10 mM Tris buffer, 1 mM EDTA solution (pH 8.0).
단리된 DNA는 제한효소 Sau3AI으로 부분 절단한 후, 25000rpmX24hr 수크로스 밀도 기울기 초원심분리법으로 절편의 크기에 따라 분획하였다. 분획된 절편은 70% 에타놀하에서 침전 진공 건조하여 2-6Kb의 DNA절편을 획득하였다.Isolated DNA was partially digested with restriction enzyme Sau3AI and fractionated according to the size of the sections by 25000 rpm × 24hr sucrose density gradient ultracentrifugation. Fractionated sections were precipitated and vacuum dried under 70% ethanol to obtain 2-6 Kb DNA fragments.
획득된 DNA 절편은 제한효소 BamHI으로 절단된 pUC18 벡터에 라이게이션(ligation) 하였으며, 이를 E.Coli JM109 균주에 형질전환하여 항생제(Ampicillin 50ug/ml)가 함유된 평판배지하에서 성장성이 있는 균을 선별하였다.The obtained DNA fragment was ligated to the pUC18 vector digested with the restriction enzyme BamHI, which was transformed into the E. Coli JM109 strain, and screened for growth bacteria under plate medium containing antibiotics (Ampicillin 50ug / ml). It was.
(2) 아세틸에스테레라제 양성 균주의 선별(2) Selection of Acetyl Esterase Positive Strains
클로닝된 유전자로부터 아세틸에스테라제 활성을 지닌 균주선별을 위하여 에틸렌 글리세롤 모노에틸 에스테르에 용해된 알파-나프텔아세테이트 20mg을 파스트 블루 RR 염(Fast blue RR salt) 12mg이 용해된 트리스-말레이트산 완충용액(pH7.6)을 첨가하여 평판배지에 도말 한 후 균체를 레플리카 방법에 의해 알파-나프텔아세테이트에 대해 분해성이 있는 적갈색의 균을 분리하였다.For screening strains with acetylesterase activity from cloned genes, 20 mg of alpha-naphtelacetate dissolved in ethylene glycerol monoethyl ester was tris-maleate buffered with 12 mg of fast blue RR salt. After adding the solution (pH7.6) to the plate medium, the cells were separated by red replicas of reddish brown bacteria with respect to alpha-naphtel acetate by the replica method.
(3) 양성 클론의 유전자 염기서열 분석(3) Gene sequencing of positive clones
재조합된 플라스미드는 플라스미드 단리 키트(Flex-prep kit: Pharmacia 제품)하에서 분리하여 플라스미드 제한효소 지도를 조사한 결과 2.7Kb의 DNA 절편으서 약1.6Kb(pSPF1.6)위치에 제한효소 Sph I 절단 부위를 가지고 있었으며, 이 부위내에서 동일한 효소활성도를 보이고 있었다. 1.6Kb의 DNA 절편은 제한효 소 Sau3AI으로 부분절단하여 그 절편들을 크로닝벡터인 pUC18 플라스미드에 0.4Kb, 0.8Kb, 1.0Kb, 1.3Kb에 해당되는 DNA 단편을 가지는 서브클론들로 재크로닝하였다. 이러한 서브클론들은 유전자 염기서열 분석 장치(Cy5TM AutoReadTM sequencing kit: Pharmacia제품)하에서 제시된 표준반응 조건에 의해 진행하였으며, 이를 준비된 유전자 자동 염기서열 분석 장치(ALF express automatic sequencer: Pharmacia제품)를 이용하여 정방향과 역방향의 상보적 염기서열을 동시에 약 500bp를 읽는 방법으로 크로닝된 유전자 염기서열을 확인 하였다. 확인된 염기서열은 중복된 부분을 연결하여 전체적인 1562bp 유전자 염기서열을 확인하였으며, 그 결과는 서열목록1과 같다.Recombinant plasmids were separated under a plasmid isolation kit (Flex-prep kit, manufactured by Pharmacia) and examined for plasmid restriction maps, and the restriction enzyme Sph I cleavage site was located at about 1.6 Kb (pSPF1.6) in 2.7 Kb DNA fragment And showed the same enzyme activity in this site. DNA fragments of 1.6 Kb were partially cut into restriction enzyme Sau3AI and the fragments were re-cloned into subclones with DNA fragments corresponding to 0.4 Kb, 0.8 Kb, 1.0 Kb, and 1.3 Kb in the pUC18 plasmid, the cloning vector. . These subclones were subjected to the standard reaction conditions presented under the Cy5TM AutoReadTM sequencing kit (Pharmacia), which were prepared using the ALF express automatic sequencer (Pharmacia). The cloned gene sequence was confirmed by reading about 500bp of complementary sequences in the reverse direction. The identified nucleotide sequences were linked to overlapping portions to identify the entire 1562 bp gene sequence, and the results are shown in SEQ ID NO: 1.
(4) 유전자 검색(4) gene search
결정된 유전자 염기서열은 효소정제과정에서 확인된 분자량(dimer 48KDa:24KDa subunit), 10개의 아미노말단 아미노산 서열(Ala-Asn-His-Ile- Tyr-Leu-Ala-Gly-Asp-Ser) 및 아미노산 전사 시작 부위(open reading frame) 분석을 통해 활성효소의 구조유전자부분(581~1235 부분)을 결정하였다. 이러한 유전자부위는 유전자 은행(NIH BLASTN search)에서 상동성 검색을 한결과 기능이 알려지지 않은 바실루스 서브틸리스 유전자(Bacillus subtilis complete genome)의 172923에서 173602부분과 93% 상동성을 보이고 있었으며, 신규의 기능을 가진 유전자임을 확인하였다.The gene sequences determined were molecular weight (dimer 48KDa: 24KDa subunit), 10 amino-terminal amino acid sequences (Ala-Asn-His-Ile-Tyr-Leu-Ala-Gly-Asp-Ser) and amino acid transcription identified during enzymatic purification. The structural gene region (581-1235) of the active enzyme was determined by analysis of the open reading frame. This gene region was 93% homologous to 173602 in 172923 of the Bacillus subtilis complete genome, whose function was unknown as a result of homology search in the NIH BLASTN search. It was confirmed that the gene having a.
이 부위의 구조유전자에 의해 코딩되는 아미노산 서열과 본 발명의 재조합된 유전자 염기서열에 의해 코딩되는 아미노산 서열을 분석 결과, 총217개의 아미노산중 4개(부위:127, 128, 176, 217) 부위에서만 차이를 보이고 있다. 이러한 결과는 동일기능의 효소가 균 종류에 따라 부분적 아미노산서열의 차이성을 보이고 있었으며, 그 기능은 동일할 것으로 판단된다. 바실루스 서브틸리스 유전자 부위의 추정 아미노산서열과 본 발명의 재조합유전자의 아미노산서열과의 상동성 비교 결과는 서열목록2와 같다.As a result of analyzing the amino acid sequence encoded by the structural gene of this region and the amino acid sequence encoded by the recombinant gene sequence of the present invention, only four of 217 amino acids (site: 127, 128, 176, 217) were identified. The difference is showing. These results showed that the enzymes of the same function showed partial amino acid sequence differences according to the types of bacteria, and the function would be the same. The result of homology comparison between the putative amino acid sequence of the Bacillus subtilis gene region and the amino acid sequence of the recombinant gene of the present invention is shown in SEQ ID NO: 2.
실시예 3 : 유전자 발현Example 3: Gene Expression
(1)유전자의 PCR증폭(1) PCR amplification of genes
상기의 실시예2)에서 추정된 구조유전자 부위를 기준으로, 5부위에 제한효소 Nco I 절단부위를 포함한 21bp, 3부위에 제한효소 Hind III 절단부위를 포함하는 22bp의 올리고뉴클레오타이드 프라이머를 합성하였으며, 이를 세팔로스포린디아세틸레이즈 유전자 증폭을 위한 PCR(Polymerase Chain Reaction)을 위한 프라이머로 이용하였다. 디자인된 프라이머의 염기서열은 다음과 같다.Based on the structural gene region estimated in Example 2), oligonucleotide primers of 21bp including restriction enzyme Nco I cleavage site at 5 sites and 22bp containing restriction enzyme Hind III cleavage site at 3 sites were synthesized. This was used as a primer for PCR (Polymerase Chain Reaction) for cephalosporin diacetylase gene amplification. The base sequence of the designed primer is as follows.
1. 5-TGA GCC ATG GCG AAT CAC ATT-35-TGA GCC ATG GCG AAT CAC ATT-3
Nco INco I
2. 5-TCA CAA GCT TCA CCC TTC TTT G-32. 5-TCA CAA GCT TCA CCC TTC TTT G-3
Hind IIIHind III
pSPF1.6 프라스미드를 모체로하여 실시예4)에서 디자인된 프라이머와 태그 DNA 폴리머라아제(Taq DNA polymerase)를 혼합하여 55℃ 60sec, 72℃ 90sec, 95℃ 60sec의 사이클을 30회 반복수행하여 654bp에 해당되는 세팔로스포린디아세틸레이즈의 구조유전자를 대량 증폭하였다.The primers designed in Example 4) and the tag DNA polymerase were mixed using pSPF1.6 prasmid as a parent, and repeated cycles of 55 ° C. 60 sec, 72 ° C. 90 sec, and 95 ° C. 60 sec were repeated 30 times. The structural gene of cephalosporin diacetylase corresponding to 654bp was mass amplified.
(2) 발현벡터의 구성 및 재조합 대장균 제조(2) Construction of Expression Vector and Preparation of Recombinant E. Coli
증폭된 유전자는 제한효소 Nco I, Hind III로 절단하였으며, 동일한 방법(pKK223-3: Sma I, Hind III)으로 절단된 발현 벡터인 pKK223-3(Pharmacia제품:암피실린 내성), pTrc99A(Pharmacia 제품: 암피실린 내성), pET24d(+)(Novagen제품: 가나마이신 내성)에 라이게이션하여 E.Coli JM109 균주에 형질전환 하여 각각 pDSTA654, pDST654, pDSET654를 구성하였으며, pDSET654는 다시 발현용 숙주인 BL21(pLys S)에 재도입하여 도 1과 같이 숙주-벡터 시스템을 재구성 하여 재조합 대장균 KFCC11029를 제조하였다.The amplified gene was digested with restriction enzymes Nco I, Hind III, pKK223-3 (Pharmacia: Ampicillin resistance), pTrc99A (Pharmacia: Pharmacia: expression vector), which were cut by the same method (pKK223-3: Sma I, Hind III). Ampicillin resistance) and pET24d (+) (Novagen product: kanamycin resistance) were ligated into E.Coli JM109 strains to construct pDSTA654, pDST654 and pDSET654, respectively, and pDSET654 was again expressed as BL21 (pLys S). ) And the host-vector system was reconstituted as in FIG. 1 to prepare recombinant E. coli KFCC11029.
(3) 유전자 발현(3) gene expression
재조합된 각 균체를 100ml LB배지하에서 37℃에서 12시간 배양하여 벡터의 특성에 따라 0.5mM IPTG나 배양온도를 전환시킴으로서 발현을 유도하였다. 이를 5000rpmx10 원심분리한후의 균체를 회수하였으며, 이를 10mM 트리스완충액(Tris HCl buffer(pH7.0)), 1mM EDTA 용액 10mL하에서 현탁하였다. 이를 초음파 파쇄기로 10sec x 4회 처리한 후 13000rpm x 10분 원심분리하여 상층액을 유전자 발현도 조사를 위한 재료로 하였다.Recombinant cells were incubated for 12 hours at 37 ° C. under 100 ml LB medium to induce expression by converting 0.5 mM IPTG or culture temperature according to the characteristics of the vector. The cells were recovered after centrifugation at 5000 rpm, and suspended in 10 mM Tris buffer (Tris HCl buffer, pH 7.0) and 1 mL EDTA solution. This was treated with an ultrasonic crusher for 10 sec x 4 times, and then centrifuged at 13000 rpm x 10 minutes to prepare the supernatant as a material for gene expression.
이를 SDS-폴리아크릴아마이드 겔 전기영동법에 의해 E.Coli JM109(pUC18)균을 비교군으로 하여 24KDa에 해당되는 단백질의 발현 정도를 확인하였으며, 증폭된 양은 플라스미드의 특성에 따라 다소의 차이를 보이고 있으나 모두 대량으로 발현됨을 확인하였다.This was confirmed by SDS-polyacrylamide gel electrophoresis and the expression level of the protein corresponding to 24KDa using E. Coli JM109 (pUC18) as a comparison group. All were confirmed to be expressed in large quantities.
효소반응을 위한 기질로서는 7-ACA를 10mM 트리스 완충용액(pH8.0)하에서 5mg/ml농도로 녹인 후 50mM 트리스 완충용액(pH7.0)에 최종농도 1mg/ml 7-ACA를 첨가하여 30℃하에서 30분 반응하여 디아세틸7-ACA의 생성량을 HPLC하에서 정량하였다. 균체파쇄액으로부터 단백질의 양은 브래드포드(Bradford) 정량법에 의해 표준 단백질양과 비교 결정하였으며, 재조합된 유전자의 발현 효소 생산 역가는 표와 같다.As a substrate for enzymatic reaction, 7-ACA was dissolved at 5 mg / ml in 10 mM Tris buffer (pH8.0), and the final concentration of 1 mg / ml 7-ACA was added to 50 mM Tris buffer (pH7.0) at 30 ° C. Reaction for 30 minutes was performed to quantify the amount of diacetyl7-ACA under HPLC. The amount of the protein from the cell lysate was determined by comparison with the standard protein amount by the Bradford assay, and the expression enzyme production titers of the recombinant genes are shown in the table.
표 5. 재조합 유전자의 발현효소 생산역가Table 5. Expression enzyme production titers of recombinant genes
실시예 4 : 균체배양 및 고정화Example 4 Cell Culture and Immobilization
(1) 균체의 배양(1) Cultivation of Cells
균체배양에 이용된 배지는 글루코즈 0.2%, 효소추출물 3%, NaCl 0.25%, pH7.2를 접종배지로 하여 37℃에서 12hr 배양한 후 동일배지하에서 5L 발효조에 교반속도 400rpm, 에어주입량 1V/V/M의 조건으로 배양하였으며, 당이 고갈되는 시점에서 최종농도가 효소추출물 5.6%, NaCl 0.4%, 글루코즈 3.4%가 되게 추가배지를 주입하며 균체를 배양하였다. 유전자 발현은 균체의 성장 곡선상에서 성숙기 단계에 도달할 시점에 500uM IPTG를 첨가하여 유전자 발현을 유도하였으며, 이후 4시간의 배양을 지속한 후 균체는 원심분리기에서 4000rpm x 20min 원심분리하여 균체를 수집하였다.The culture medium used for cell culture was 0.2% glucose, 3% enzyme extract, 0.25% NaCl, pH7.2 and incubated for 12hr at 37 ° C, and then stirred at 400rpm in a 5L fermenter under the same medium. The cells were cultured under the condition of / M, and the cells were cultured by injecting additional medium so that the final concentration was 5.6% of enzyme extract, 0.4% of NaCl, and 3.4% of glucose. Gene expression was induced by the addition of 500uM IPTG at the time of reaching the maturation stage on the growth curve of the cells, and after 4 hours of incubation, the cells were collected by centrifugation at 4000rpm x 20min in a centrifuge. .
(2) 균체고정화(2) Cell fixation
수집된 균은 10mM 트리스 완충용액(pH9.0), 1mM EDTA하의 완충용액에서 재현탁하여 40℃에서 1시간 교반한 후 원심분리하여 재수집하였다. 수집된 8g(wet weight)의 균체는 40℃, 0.9% NaCl, 0.2% 트라톤 엑스-100(Triton X-100) 8ml하에서 재현탁하였다. 동시에 2.07g 카르지난(κ-carrageenan)을 0.9% NaCl 45ml, 80℃에서 녹인 후 45℃까지 식혀 두 용액을 혼합하여 10℃에서 30분동안 다시 냉각하였다. 이때 겔의 강도를 증가하기 위하여 0.3M KCl하에 적셔서 고정화된 균을 획득하였다.The collected bacteria were resuspended in 10 mM Tris buffer solution (pH9.0), buffer solution under 1 mM EDTA, stirred at 40 ° C for 1 hour, and then collected by centrifugation. The collected 8 g (wet weight) cells were resuspended at 8 ° C. at 40 ° C., 0.9% NaCl, 0.2% Triton X-100. At the same time, 2.07g κ-carrageenan was dissolved in 45 ml of 0.9% NaCl, 80 ° C, cooled to 45 ° C, and the two solutions were mixed and cooled again at 10 ° C for 30 minutes. At this time, in order to increase the strength of the gel, it was soaked under 0.3 M KCl to obtain a fixed bacteria.
(3) 효소고정화(3) enzyme fixation
수집된 균체는 10mM 트리스 완충용액(pH7.0), 1mM EDTA 용액에서 20% 농도로 현탁하였다. 이를 유압식 균체 파쇄기에서 균체를 파쇄한 후 20mM MgCl2를 첨가하고 1U/ml 농도로 데옥시리보뉴클라아제(Deoxyribonuclease I) 효소를 처리하여 상온에서 1시간 교반하며 핵산을 가수분해하였다. 이러한 용액은 미세여과하여, 세포찌거기 및 비활성 펩타이드를 제거하여 효소고정화를 위한 시료로 이용하였다.The collected cells were suspended at 20% concentration in 10 mM Tris buffer (pH 7.0), 1 mM EDTA solution. The cells were crushed in a hydraulic cell crusher, 20mM MgCl 2 was added, and treated with deoxyribonuclease I at a concentration of 1 U / ml, and stirred at room temperature for 1 hour to hydrolyze the nucleic acid. This solution was microfiltered to remove cell debris and inactive peptides and used as a sample for enzyme fixation.
효소 고정화 과정은 유포지트 씨(Eupergit-C:독일 Rhm 제품)의 표준방법에 따라 100ml(역가 880U/ml, 총 88,000units)을 1.0M (K2HPO4+KH2PO4 )(pH7.5) 완충용액하에 20g 유포지트 씨 담체와 혼합하여 상온에서 3일간 정치하였다.Enzyme immobilization process was carried out using 100 ml (titer 880 U / ml, total 88,000 units) in 20 ml of 1.0 M (K2HPO4 + KH2PO4) (pH7.5) buffer according to the standard method of Eupositit C (Eupergit-C: German Rhm). The mixture was allowed to stand for 3 days at room temperature by mixing with the seed carrier.
이러한 반응혼합물은 0.1M (K2HPO4+KH2PO4 )(pH7.5) 완충용액을 이용하여 필터링하며 세척하여 냉장보관하였다.The reaction mixture was filtered and washed with 0.1 M (K2HPO4 + KH2PO4) (pH7.5) buffer, and stored in the refrigerator.
실시예 5 : 고정화에 의한 탈아세틸화 반응Example 5 Deacetylation by Immobilization
발명의 효소반응에 의해 전환된 산물의 구조는 다음과 같다.The structure of the product converted by the enzymatic reaction of the invention is as follows.
반응기질(7-ACA) 20g을 정량하여 1L의 100mM 카보네이트 나트륨 완충용액(pH7.5) 하에 녹인 후 반응기의 고정화효소와 교반하였다.20 g of the reactive mass (7-ACA) was quantified and dissolved in 1 L of 100 mM sodium carbonate buffer (pH 7.5), followed by stirring with immobilized enzyme of the reactor.
이때 반응이 진행됨에 따라 발생되는 탈아세틸화된 초산에 의해, pH가 강하되는 것을 방지하기 위하여 1N KOH을 첨가하였으며, 반응pH를 7.9 - 8.2수준으로 조절하며 반응을 진행하였다. 반응온도는 30℃를 유지하였으며, KOH의 첨가가 종결되는 시점에서 반응을 종결하였다.At this time, 1N KOH was added to prevent the pH from dropping by the deacetylated acetic acid generated as the reaction proceeded, and the reaction proceeded by adjusting the reaction pH to 7.9-8.2 level. The reaction temperature was maintained at 30 ℃, the reaction was terminated at the end of the addition of KOH.
반응기질(2% 농도)이 탈아세틸화 되는데 약40분의 반응시간이 소요되었다. 진행된 반응산물은 HPLC분석에 의해 반응물을 확인한 결과 반응수율은 92% 수준이었다.It took about 40 minutes to deacetylate the reactor (2% concentration). As a result of confirming the reaction product by HPLC analysis, the reaction yield was 92%.
동일한 방법으로 고정화된 균체를 함유한 반응은 반응은 균체막을 통과하는 기질의 투과성에 의해 반응성이 제한되었으며, 진행된 반응물의 분석에 의한 반응수율은 고정화 효소에 비해 낮은 44% 수준을 보였다.Reactions containing immobilized cells in the same way were limited in reactivity by the permeability of the substrate through the cell membrane, and the reaction yield by analysis of the reactants was 44% lower than that of the immobilized enzyme.
[서열목록][Sequence list]
서열번호(SEQ ID NO.) : 1SEQ ID NO .: 1
서열의 길이 : 1562Sequence length: 1562
서열의 타입 : 핵산Type of sequence: nucleic acid
쇄의 수 : 2본쇄Number of chains: 2 prints
토폴로지 : 직쇄상Topology: linear
서열의 종류 : Gemonic DNAType of sequence: Gemonic DNA
기원origin
생물명 : 바실러스종Biology: Bacillus Species
주명 : DS1152 (KFCC11026)Main Name: DS1152 (KFCC11026)
서열:order:
ATCGAGCTCG GTACCGGGGA TCATGACTGG GACGGAACGG TCGGCAGGCC 50ATCGAGCTCG GTACCGGGGA TCATGACTGG GACGGAACGG TCGGCAGGCC 50
GAAGATTGAA AAGTGGGATG CTGAAAACCG CTGTCTGAAG ACGATTTTTC 100GAAGATTGAA AAGTGGGATG CTGAAAACCG CTGTCTGAAG ACGATTTTTC 100
AGCCGGACGG CGTGCTGTCC AACAACGGCA CAAAAGGAAA TCCTGTTCTT 150AGCCGGACGG CGTGCTGTCC AACAACGGCA CAAAAGGAAA TCCTGTTCTT 150
CAGGCCAACC TGTTCGGAGA CTGGCGGGAA GAAGTGATAT GGAGAACGGA 200CAGGCCAACC TGTTCGGAGA CTGGCGGGAA GAAGTGATAT GGAGAACGGA 200
AGACAGCAGC GCACTCCGCA TCTATACAAC GACACATCTC ACCCGCCATC 250AGACAGCAGC GCACTCCGCA TCTATACAAC GACACATCTC ACCCGCCATC 250
GCTTTTACAC GCTTATGCAC GATCCGGTTT ACAGGCTCGG CATCGCCTGG 300GCTTTTACAC GCTTATGCAC GATCCGGTTT ACAGGCTCGG CATCGCCTGG 300
CAGAATACCG CCTACAACCA GCCGCCGCAC ACGGGCTTTT ATCTCGGAAC 350CAGAATACCG CCTACAACCA GCCGCCGCAC ACGGGCTTTT ATCTCGGAAC 350
GGGAATGAAA AAACCACCGA AGCCCGCCCT GTACATAGCG GGCAGCAAAG 400GGGAATGAAA AAACCACCGA AGCCCGCCCT GTACATAGCG GGCAGCAAAG 400
CGGAGGCGCC GCTATAGGAG GAACTAAGGG ATAAGAAGCA AAGGCTGAAC 450CGGAGGCGCC GCTATAGGAG GAACTAAGGG ATAAGAAGCA AAGGCTGAAC 450
AGTACGACAA GATGACTTAT CAAAGCCAGG ACGACTAATG TTCAGGCGCT 500AGTACGACAA GATGACTTAT CAAAGCCAGG ACGACTAATG TTCAGGCGCT 500
GAAATCACCG GTTTTTTCAA GGGAAGAGCT GTCCATGATT GATGCCATAT 550GAAATCACCG GTTTTTTCAA GGGAAGAGCT GTCCATGATT GATGCCATAT 550
GAAACGAAAA AAACGAGGGG GAATGAGAA ATG GCG AAT CAC ATT TAT 597GAAACGAAAA AAACGAGGGG GAATGAGAA ATG GCG AAT CAC ATT TAT 597
1 Met Ala Asn His Ile Tyr 61 Met Ala Asn His Ile Tyr 6
CTT GCT GGC GAT TCA ACT GTT CAA ACG TAT GGA GAC AGC ACA 639CTT GCT GGC GAT TCA ACT GTT CAA ACG TAT GGA GAC AGC ACA 639
Leu Ala Gly Asp Ser Thr Val Gln Thr Tyr Gly Asp Ser Thr 20Leu Ala Gly Asp Ser Thr Val Gln Thr Tyr Gly Asp Ser Thr 20
AAT CAA GGG GGG TGG GGG CAG TTT CTC GGC TCG CAT CTG CCG 681AAT CAA GGG GGG TGG GGG CAG TTT CTC GGC TCG CAT CTG CCG 681
Asn Gln Gly Gly Trp Gly Gln Phe Leu Gly Ser His Leu Pro 34Asn Gln Gly Gly Trp Gly Gln Phe Leu Gly Ser His Leu Pro 34
GAG CAT ATT CAA GTG ATT AAC AGA GCA ATC GGG GGA AGA AGC 723GAG CAT ATT CAA GTG ATT AAC AGA GCA ATC GGG GGA AGA AGC 723
Glu His Ile Gln Val Ile Asn Arg Ala Ile Gly Gly Arg Ser 48Glu His Ile Gln Val Ile Asn Arg Ala Ile Gly Gly Arg Ser 48
TCG AAA ACA TTT GTG GAA GAG GGC AGG CTT CAG GCG ATT CTT 765TCG AAA ACA TTT GTG GAA GAG GGC AGG CTT CAG GCG ATT CTT 765
Ser Lys Thr Phe Val Glu Glu Gly Arg Leu Gln Ala Ile Leu 62Ser Lys Thr Phe Val Glu Glu Gly Arg Leu Gln Ala Ile Leu 62
GAT GTG ATT GAG CCG GAT GAC TGG CTG TTT GTG CAG ATG GGC 807GAT GTG ATT GAG CCG GAT GAC TGG CTG TTT GTG CAG ATG GGC 807
Asp Val Ile Glu Pro Asp Asp Trp Leu Phe Val Gln Met Gly 76Asp Val Ile Glu Pro Asp Asp Trp Leu Phe Val Gln Met Gly 76
CAT AAT GAC GCG TCG AAA AAT AAG CCG GAG CGC TAC ACC GAG 849CAT AAT GAC GCG TCG AAA AAT AAG CCG GAG CGC TAC ACC GAG 849
His Asn Asp Ala Ser Lys Asn Lys Pro Glu Arg Tyr Thr Glu 90His Asn Asp Ala Ser Lys Asn Lys Pro Glu Arg Tyr Thr Glu 90
CCC TAT ACC ACC TAT AAA CAA TAT TTA AAG CAG TAT ATC GCA 891CCC TAT ACC ACC TAT AAA CAA TAT TTA AAG CAG TAT ATC GCA 891
Pro Tyr Thr Thr Tyr Lys Gln Tyr Leu Lys Gln Tyr Ile Ala 104Pro Tyr Thr Thr Tyr Lys Gln Tyr Leu Lys Gln Tyr Ile Ala 104
GGC GCG CGG GAA AAA GGC GCC CAT CCG CTT CTC ATT ACC CCT 933GGC GCG CGG GAA AAA GGC GCC CAT CCG CTT CTC ATT ACC CCT 933
Gly Ala Arg Glu Lys Gly Ala His Pro Leu Leu Ile Thr Pro 118Gly Ala Arg Glu Lys Gly Ala His Pro Leu Leu Ile Thr Pro 118
GTA GCA CGC TTT CAT TAT GAA AAT GAC ATG TTT TTG AAC GAC 975GTA GCA CGC TTT CAT TAT GAA AAT GAC ATG TTT TTG AAC GAC 975
Val Ala Arg Phe His Tyr Glu Asn Asp Met Phe Leu Asn Asp 132Val Ala Arg Phe His Tyr Glu Asn Asp Met Phe Leu Asn Asp 132
TTT CCT GAC TAT TGC ATT GCC ATG AAG CAG ACG GCT GCT GAG 1017TTT CCT GAC TAT TGC ATT GCC ATG AAG CAG ACG GCT GCT GAG 1017
Phe Pro Asp Tyr Cys Ile Ala Met Lys Gln Thr Ala Ala Glu 146Phe Pro Asp Tyr Cys Ile Ala Met Lys Gln Thr Ala Ala Glu 146
GAG AAT GTC CAG CTC ATT GAT CTG ATG GAG AAA AGT CTT GCT 1059GAG AAT GTC CAG CTC ATT GAT CTG ATG GAG AAA AGT CTT GCT 1059
Glu Asn Val Gln Leu Ile Asp Leu Met Glu Lys Ser Leu Ala 160Glu Asn Val Gln Leu Ile Asp Leu Met Glu Lys Ser Leu Ala 160
TTC TTT ACC GAG AAG GGC GAG GAA AAA GTG TAC ACC TAT TTT 1101TTC TTT ACC GAG AAG GGC GAG GAA AAA GTG TAC ACC TAT TTT 1101
Phe Phe Thr Glu Lys Gly Glu Glu Lys Val Tyr Thr Tyr Phe 174Phe Phe Thr Glu Lys Gly Glu Glu Lys Val Tyr Thr Tyr Phe 174
ATG GTG TCA GAA GGA ATT AAC GAT TAC ACG CAC TTT ACA AAA 1143ATG GTG TCA GAA GGA ATT AAC GAT TAC ACG CAC TTT ACA AAA 1143
Met Val Ser Glu Gly Ile Asn Asp Tyr Thr His Phe Thr Lys 188Met Val Ser Glu Gly Ile Asn Asp Tyr Thr His Phe Thr Lys 188
AAA GGC GCA AAT GAA ATG GCG AAA CTT GTG GCA AAA GGC ATA 1185AAA GGC GCA AAT GAA ATG GCG AAA CTT GTG GCA AAA GGC ATA 1185
Lys Gly Ala Asn Glu Met Ala Lys Leu Val Ala lys Gly Ile 202Lys Gly Ala Asn Glu Met Ala Lys Leu Val Ala lys Gly Ile 202
AAG GAA CTC GGC CTG CCA TTG ACA GAA TCG ATC ATC AAA GAA 1227AAG GAA CTC GGC CTG CCA TTG ACA GAA TCG ATC ATC AAA GAA 1227
Lys Glu Leu Gly Leu Pro Leu Thr Glu Ser Ile Ile Lys Glu 216Lys Glu Leu Gly Leu Pro Leu Thr Glu Ser Ile Ile Lys Glu 216
GGG TGA AAA ATG TGA GGA GAAAACTG TATCACGGCG CTTGTTATTA 1273GGG TGA AAA ATG TGA GGA GAAAACTG TATCACGGCG CTTGTTATTA 1273
Gly *** 217Gly *** 217
TCCCGAATTA TGGGATGAAG AGACGATTCA GCAGGACATT GACATCATGC 1323TCCCGAATTA TGGGATGAAG AGACGATTCA GCAGGACATT GACATCATGC 1323
GTGAAGTTGG CGTGAATGTT GTGCGGATCG GTGAATTTGC CTGGTCTGTC 1373GTGAAGTTGG CGTGAATGTT GTGCGGATCG GTGAATTTGC CTGGTCTGTC 1373
ATGGAACCGG AAGAAGGAAA AATTGACGTC AGTTTTTTCA AAGAGATCAT 1423ATGGAACCGG AAGAAGGAAA AATTGACGTC AGTTTTTTCA AAGAGATCAT 1423
CACCCGTCTG TATGATAACG GCATCGAAAC GATCATGTGC ACGCCGACGC 1473CACCCGTCTG TATGATAACG GCATCGAAAC GATCATGTGC ACGCCGACGC 1473
CTACACCGCC GATTTGGCTG TCGCACGGCC GGCCGGAGCG TATGCATGTA 1523CTACACCGCC GATTTGGCTG TCGCACGGCC GGCCGGAGCG TATGCATGTA 1523
AACGAAAAAA GAGAGGTCAT GGGGCATGGC TCCCGTCAG 1562AACGAAAAAA GAGAGGTCAT GGGGCATGGC TCCCGTCAG 1562
[서열목록][Sequence list]
서열번호(SEQ ID NO.) : 2SEQ ID NO .: 2
서열의 길이 : 217Length of sequence: 217
서열의 타입 : 아미노산Type of sequence: amino acid
쇄의 수 : 1본쇄Number of chains: 1 chain
토폴로지 : 선형Topology: linear
서열의 종류 : 단백질Type of sequence: protein
기원origin
생물명 : 바실러스종Biology: Bacillus Species
주명 : DS1152 (KFCC11026)Main Name: DS1152 (KFCC11026)
서열:order:
A Met Ala Asn His Ile Ty Leu Ala Gly Asp Ser Thr Val Gln Thr Tyr 16A Met Ala Asn His Ile Ty Leu Ala Gly Asp Ser Thr Val Gln Thr Tyr 16
B Met Ala Asn His Ile Ty Leu Ala Gly Asp Ser Thr Val Gln Thr Tyr 16B Met Ala Asn His Ile Ty Leu Ala Gly Asp Ser Thr Val Gln Thr Tyr 16
A Gly Asp Ser Thr Asn Gln Gly Gly Trp Gly Gln Phe Leu Gly Ser His 32A Gly Asp Ser Thr Asn Gln Gly Gly Trp Gly Gln Phe Leu Gly Ser His 32
B Gly Asp Ser Thr Asn Gln Gly Gly Trp Gly Gln Phe Leu Gly Ser His 32B Gly Asp Ser Thr Asn Gln Gly Gly Trp Gly Gln Phe Leu Gly Ser His 32
A Leu Pro Glu His Ile Gln Val Ile Asn Arg Ala Ile Gly Gly Arg Ser 48A Leu Pro Glu His Ile Gln Val Ile Asn Arg Ala Ile Gly Gly Arg Ser 48
B Leu Pro Glu His Ile Gln Val Ile Asn Arg Ala Ile Gly Gly Arg Ser 48B Leu Pro Glu His Ile Gln Val Ile Asn Arg Ala Ile Gly Gly Arg Ser 48
A Ser Lys Thr Phe Val Glu Glu Gly Arg Leu Gln Ala Ile Leu Asp Val 64A Ser Lys Thr Phe Val Glu Glu Gly Arg Leu Gln Ala Ile Leu Asp Val 64
B Ser Lys Thr Phe Val Glu Glu Gly Arg Leu Gln Ala Ile Leu Asp Val 64B Ser Lys Thr Phe Val Glu Glu Gly Arg Leu Gln Ala Ile Leu Asp Val 64
A Ile Glu Pro Asp Asp Trp Leu Phe Val Gln Met Gly His Asn Asp Ala 80A Ile Glu Pro Asp Asp Trp Leu Phe Val Gln Met Gly His Asn Asp Ala 80
B Ile Glu Pro Asp Asp Trp Leu Phe Val Gln Met Gly His Asn Asp Ala 80B Ile Glu Pro Asp Asp Trp Leu Phe Val Gln Met Gly His Asn Asp Ala 80
A Ser Lys Asn Lys Pro Glu Arg Tyr Thr Glu Pro Tyr Thr Thr Tyr Lys 96A Ser Lys Asn Lys Pro Glu Arg Tyr Thr Glu Pro Tyr Thr Thr Tyr Lys 96
B Ser Lys Asn Lys Pro Glu Arg Tyr Thr Glu Pro Tyr Thr Thr Tyr Lys 96B Ser Lys Asn Lys Pro Glu Arg Tyr Thr Glu Pro Tyr Thr Thr Tyr Lys 96
A Gln Tyr Leu Lys Gln Tyr Ile Ala Gly Ala Arg Glu Lys Gly Ala His 112A Gln Tyr Leu Lys Gln Tyr Ile Ala Gly Ala Arg Glu Lys Gly Ala His 112
B Gln Tyr Leu Lys Gln Tyr Ile Ala Gly Ala Arg Glu Lys Gly Ala His 112B Gln Tyr Leu Lys Gln Tyr Ile Ala Gly Ala Arg Glu Lys Gly Ala His 112
A Pro Leu Leu Ile Thr Pro Val Ala Arg Phe His Tyr Glu Asn Asp Met 128A Pro Leu Leu Ile Thr Pro Val Ala Arg Phe His Tyr Glu Asn Asp Met 128
B Pro Leu Leu Ile Thr Pro Val Ala Arg Phe His Tyr Glu Asn Gly Val 128B Pro Leu Leu Ile Thr Pro Val Ala Arg Phe His Tyr Glu Asn Gly Val 128
A Phe Leu Asn Asp Phe Pro Asp Tyr Cys Ile Ala Met Lys Gln Thr Ala 144A Phe Leu Asn Asp Phe Pro Asp Tyr Cys Ile Ala Met Lys Gln Thr Ala 144
B Phe Leu Asn Asp Phe Pro Asp Tyr Cys Ile Ala Met Lys Gln Thr Ala 144B Phe Leu Asn Asp Phe Pro Asp Tyr Cys Ile Ala Met Lys Gln Thr Ala 144
A Ala Glu Glu Asn Val Gln Leu Ile Asp Leu Met Glu Lys Ser Leu Ala 160A Ala Glu Glu Asn Val Gln Leu Ile Asp Leu Met Glu Lys Ser Leu Ala 160
B Ala Glu Glu Asn Val Gln Leu Ile Asp Leu Met Glu Lys Ser Leu Ala 160B Ala Glu Glu Asn Val Gln Leu Ile Asp Leu Met Glu Lys Ser Leu Ala 160
A Phe Phe Thr Glu Lys Gly Glu Glu Lys Val Tyr Thr Tyr Phe Met Val 176A Phe Phe Thr Glu Lys Gly Glu Glu Lys Val Tyr Thr Tyr Phe Met Val 176
B Phe Phe Thr Glu Lys Gly Glu Glu Lys Val Tyr Thr Tyr Phe Met Ile 176B Phe Phe Thr Glu Lys Gly Glu Glu Lys Val Tyr Thr Tyr Phe Met Ile 176
A Ser Glu Gly Ile Asn Asp Tyr Thr His Phe Thr Lys Lys Gly Ala Asn 192A Ser Glu Gly Ile Asn Asp Tyr Thr His Phe Thr Lys Lys Gly Ala Asn 192
B Ser Glu Gly Ile Asn Asp Tyr Thr His Phe Thr Lys Lys Gly Ala Asn 192B Ser Glu Gly Ile Asn Asp Tyr Thr His Phe Thr Lys Lys Gly Ala Asn 192
A Glu Met Ala Lys Leu Val Ala lys Gly Ile Lys Glu Leu Gly Leu Pro 208A Glu Met Ala Lys Leu Val Ala lys Gly Ile Lys Glu Leu Gly Leu Pro 208
B Glu Met Ala Lys Leu Val Ala lys Gly Ile Lys Glu Leu Gly Leu Pro 208B Glu Met Ala Lys Leu Val Ala lys Gly Ile Lys Glu Leu Gly Leu Pro 208
A Leu Thr Glu Ser Ile Ile Lys Glu Gly *** 217A Leu Thr Glu Ser Ile Ile Lys Glu Gly *** 217
B Leu Thr Glu Ser Ile Ile Lys Glu Arg *** 217B Leu Thr Glu Ser Ile Ile Lys Glu Arg *** 217
상기의 표에서 상위 아미노산 서열(A)은 본 발명의 아미노산 서열이며, 하위의아미노산 서열(B)은 유전자 은행에서 검색된 바실루스 서브틸리스 게놈부위의 유전자에서 추정된 아미노산 서열이다.In the above table, the upper amino acid sequence (A) is the amino acid sequence of the present invention, and the lower amino acid sequence (B) is the amino acid sequence estimated from the gene of the Bacillus subtilis genomic region searched by the gene bank.
본 발명은 미생물로부터 신규의 효소를 유전자 재조합법에 의해 대량생산하였다. 생산된 효소는 세파로스포린계열의 항생제 제조에 필수적인 전구체인, 디아세틸 세팔로스포린C 및 디아세틸7-ACA를 효소적 방법에 의해 제조한다.The present invention mass-produced new enzymes from microorganisms by genetic recombination. The enzyme produced produces diacetyl cephalosporin C and diacetyl7-ACA, which are essential precursors for the preparation of antibiotics of the cephalosporin family, by enzymatic methods.
본 발명의 효소를 세팔로스포린C와 7-ACA의 탈아세틸화반응에 이용함으로서, 기존의 다단계 화학합성공정중 일부공정의 제거 및 단축이 가능하며, 반응부산물 생성 및 중간체의 분해를 방지 함으로서 산업적 생산수율의 향상에 기여할 수 있다.By using the enzyme of the present invention in the deacetylation reaction of cephalosporin C and 7-ACA, it is possible to remove and shorten some of the existing multi-step chemical synthesis processes, and to prevent the formation of reaction by-products and decomposition of intermediates. It can contribute to the improvement of production yield.
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019980014790A KR100270508B1 (en) | 1998-04-24 | 1998-04-24 | Novel cephalosporin diacetylase gene and protein production method using the same |
PCT/KR1998/000487 WO1999055881A1 (en) | 1998-04-24 | 1998-12-30 | Cephalosporin deacetylase, gene coding for it, and preparation method of deacetylated cephalosporin compounds using it |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019980014790A KR100270508B1 (en) | 1998-04-24 | 1998-04-24 | Novel cephalosporin diacetylase gene and protein production method using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR19990081077A KR19990081077A (en) | 1999-11-15 |
KR100270508B1 true KR100270508B1 (en) | 2001-02-01 |
Family
ID=19536687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019980014790A KR100270508B1 (en) | 1998-04-24 | 1998-04-24 | Novel cephalosporin diacetylase gene and protein production method using the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100270508B1 (en) |
WO (1) | WO1999055881A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2156812B1 (en) * | 1999-04-09 | 2002-02-01 | Antibioticos Sau | AN EXTRACELLULAR PROTEASE OF ACREMONIUM CHRYSOGENUM WITH CPC-ACETILHIDROLASA ACTIVITY AND ITS USE FOR THE SYNTHESIS OF DEACTILATED DERIVATIVES OF CEPHALOSPORIN C AND INACTIVATION OF THE GENE TO INCREASE THE PRODUCTION OF CEPHALOSPORIN. |
WO2009013611A2 (en) * | 2007-07-26 | 2009-01-29 | Orchid Chemicals & Pharmaceuticals Limited | Modified esterase and its applications |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2040707C (en) * | 1990-04-27 | 2002-07-09 | Kenji Mitsushima | Cephalosporin acetylhydrolase gene and protein encoded by said gene |
JPH088877B2 (en) * | 1990-06-19 | 1996-01-31 | 塩野義製薬株式会社 | Process for producing deacetyl-7-aminocephalosporanic acid |
-
1998
- 1998-04-24 KR KR1019980014790A patent/KR100270508B1/en not_active IP Right Cessation
- 1998-12-30 WO PCT/KR1998/000487 patent/WO1999055881A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
BLAST Search Results , emb/Z99107/BSUB0004 * |
Nature 1997 Nov 20, 390 * |
Also Published As
Publication number | Publication date |
---|---|
KR19990081077A (en) | 1999-11-15 |
WO1999055881A1 (en) | 1999-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2103364C1 (en) | Dna sequence, protein, method of protein producing | |
US6465233B1 (en) | Nucleic acid molecule encoding a cephalosporin acetylesterase | |
KR20140094150A (en) | A mutant enzyme for production of cephalosporin antibiotics | |
Geueke et al. | Heterologous expression of Rhodococcus opacus L-amino acid oxidase in Streptomyces lividans | |
CN113604445B (en) | A kind of tyrosinase and its preparation and application | |
JP4529338B2 (en) | DNA encoding hydantoinase, DNA encoding N-carbamyl-L-amino acid hydrolase, recombinant DNA, transformed cell, protein production method and optically active amino acid production method | |
CA2045839C (en) | Cloned n-methylhydantoinase | |
US7399624B2 (en) | Cephalosporin C acylases | |
JP4561009B2 (en) | DNA encoding D-hydantoin hydrolase, DNA encoding N-carbamyl-D-amino acid hydrolase, recombinant DNA containing the gene, cells transformed with the recombinant DNA, and production of proteins using the transformed cells Method and method for producing D-amino acid | |
KR100270508B1 (en) | Novel cephalosporin diacetylase gene and protein production method using the same | |
JP4437170B2 (en) | Microorganism, lactamase enzyme obtained from the microorganism, and use thereof | |
KR20070085922A (en) | Transformant expressing nitrile hydratase | |
KR102026836B1 (en) | Novel lipase gene Lip-1420 derived from soil metagenome and use thereof | |
ES2252302T3 (en) | GLUTARIL CEPHALOSPORINE AMIDASE FROM PSEUDOMONAS DIMINUTA BS-203. | |
US12024729B2 (en) | Polypeptide having cephalosporin C acylase activity and use thereof | |
KR0184755B1 (en) | Recombinant heat resistant tyrosine phenolase and method for preparing L-dopa using the same | |
RU2221868C2 (en) | Gene encoding l-asparaginase in erwinia carotovora and strain escherichia coli vkpm = b-8174 as producer of erwinia caratovora l-asparaginase | |
JP3829950B2 (en) | Novel creatinine amide hydrolase | |
RU2177998C2 (en) | Method of preparing recombinant uridine phosphorylase, recombinant plasmid dna perurph01 and strain of escherichia coli bl 21(dez)/perurph01 for its realization | |
KR100310932B1 (en) | Discovery of Staphylococcus haemolyticus L62(KCTC 8957P) producing a novel lipase and development of its efficient production method using Escherichia coli BL21(DE3)/pSHML(KCTC 8956P) | |
RU2388825C1 (en) | FERMENT CARBOXYPEPTIDASE KPSB, STRAIN Streptomyces bikiniensis-PRODUCER OF CARBOXYPEPTIDASE KPSB; FRAGMENT OF DNA SB27-995, WHICH CODES SYNTHESIS OF THIS FERMENT MATURE FORM, AND METHOD FOR MICROBIOLOGICAL SYNTHESIS OF CARBOXYPEPTIDASE KPSB | |
JPH10262674A (en) | Gene coding for alkaline phosphatase | |
JPH08205864A (en) | New cephalosporin c acylase and its production | |
KR100311891B1 (en) | Gene Coding for Heat-resistant Glutamate Racemase of Aquifex pyrophilus, Heat-resistant Glutamate Racemase Expressed therefrom, and Method for Preparing the Same | |
JPH08256771A (en) | New protein having amidase activity and gene coding the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19980424 |
|
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19980424 Comment text: Request for Examination of Application |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20000120 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20000510 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20000802 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20000803 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |